Robert J. Motzer, MD, reviews the evolving treatment paradigm, and the factors to consider when choosing frontline therapy, such as sunitinib, pazopanib, cabozantinib, or ipilimumab/nivolumab, for metastatic renal cell carcinoma.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
Ещё видео!